Table 2.
Clinical and Immunohistochemical Profiles of the Cases of Leiomyosarcoma Showing Recurrence, Metastasis, or Death
| Locations | Labeling index on IHC (%) | Clinical course (months, after surgery) | ||||
|---|---|---|---|---|---|---|
| Cyclin A | Cyclin E | cdk2 | Recurrence | Metastasis | Death | |
| CU | 14.1 | 3.6 | 28.2 | 20 | N.S. (26) | N.S. (26) |
| CU | 7.6 | 0 | 20.3 | 36 | N.S. (66) | N.S. (66) |
| SC | 6.7 | 0 | 20.8 | N.S. (60) | 52 | 60 |
| SC | 23.3 | 0 | 25.8 | 15 | N.S. (41) | N.S. (41) |
| SC | 8.5 | 0 | 45.1 | 37 | N.S. (47) | N.S. (47) |
| SC | 7.8 | 0 | 17.4 | 64 | N.S. (114) | N.S. (114) |
| IM | 29.4 | 24 | 27.6 | 10 | 23 | 28 |
| IM | 17.5 | 10.9 | 38.2 | 17 | 24 | 30 |
| IM | 8.5 | 12.0 | 10.3 | N.S. (23) | 16 | 23 |
| IM | 12.9 | 6.7 | 31.0 | 23 | 34 | 41 |
IHC, immunohistochemistry; CU, cutis (intradermal); SC, subcutaneous; IM, intramuscular; N.S., not seen.